Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Sandoz Inc., Pfizer Inc., and Amneal Pharmaceuticals Inc. are among a group of generic-drug manufacturers that will face some ...

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for ...

In this note, we will discuss the latest decisions on the merits from the Dutch patent court on the matter of plausibility and inventive step.

The two-day event will see industry experts from across the clinical trial space holding talks on subjects from AI to ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

LVMH plans to ramp up manufacturing at its Zenith brand to supply movements for timepieces across the luxury group’s watch ...